Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GQ1005 in HER2-expressing advanced solid tumors
NCT06154343Phase 1Recruiting
- Sponsor
- GeneQuantum Healthcare
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gq1005 in solid tumor, breast cancer, non-small cell lung cancer (NSCLC) and 4 more (2 arms), sponsored by GeneQuantum Healthcare. Primary endpoints: Incidence and Severity of Adverse Events up to 2 years, Dose Limiting Toxicities at 21 days and 1 more. Started Nov 2022; status: recruiting.
02
Drugs
gq1005
03
Conditions
solid tumorbreast cancernon-small cell lung cancer (NSCLC)gastric cancer (GC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06154343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06154343.